Alpha Cognition Inc. Advances ZUNVEYL Commercialization and Secures Key Regulatory Milestones

Alpha Cognition Inc. (NASDAQ: ACOG) has made notable strides in the commercialization of ZUNVEYL®, its treatment for Alzheimer's disease, during the second quarter of 2025. The drug has seen early adoption in the U.S. long-term care (LTC) market, with orders from over 300 facilities and a 65% repeat order rate, indicating strong clinical confidence. Additionally, the company achieved a significant regulatory milestone in China, further expanding its market reach.

The sales team's engagement with more than 3,700 healthcare professionals has resulted in both new and repeat prescriptions, with clinicians praising ZUNVEYL's cognitive and behavioral benefits. A key development was securing a national Medicare Part D contract without prior authorization requirements, significantly improving patient access ahead of schedule. This is particularly impactful given that Alzheimer's disease affects 7 million Americans, with more than half discontinuing treatment due to side effects.

Financially, Alpha Cognition reported $1.6M in net product sales from ZUNVEYL in 2Q25, contributing to a year-to-date net product revenue of approximately $2.0M. The company also received $0.08M in licensing revenue from a CMS partnership. Despite increased SG&A expenses due to commercialization efforts, the company maintains a strong cash position of $39.4M, ensuring operational runway for about two years at current expenditure rates.

Looking ahead, Alpha Cognition is focused on further penetrating the LTC market, with plans to secure another national contract by year-end. The company is also advancing its pipeline, including a sublingual formulation of ALPHA-1062 for patients with dysphagia or aphasia, expected to complete taste testing in 1Q26. With a valuation range of $32.69 to $43.65 based on DCF analysis, Alpha Cognition is positioned for continued growth in the Alzheimer's treatment market.

For more information on Alpha Cognition's progress and financials, visit https://www.alphacognition.com.